| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Neurocrine Biosciences, Inc. (NBIX) has 17 insiders with recent SEC Form 4 filings, including 0 buys and 4 sells. NBIX is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 140.4K | $23.05M | - | |
| Other | 52.8K | $8.66M | - | |
| Other | 46.8K | $7.68M | - | |
| Other | 39.6K | $6.51M | -36,937 | |
| Other | 36.8K | $6.05M | -11,000 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2017 | Gano Kyle54 | Chief Business Development Off | Sell | 1,625 | $40.65 | $66,056.25 | -2.7% | |
| Jan 17, 2017 | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,750 | $40.65 | $152,437.50 | -1.5% | |
| Jan 17, 2017 | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 1,625 | $40.63 | $66,023.75 | -1.4% | |
| Jan 17, 2017 | Obrien Christopher Flint | Chief Medical Officer | Sell | 1,750 | $40.66 | $71,155.00 | -5.0% |